Shares of Co-Diagnostics Inc (NASDAQ:CODX) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Analysts have set a twelve-month consensus price target of $2.00 for the company and are predicting that the company will post ($0.03) EPS for the current quarter, according to Zacks. Zacks has also given Co-Diagnostics an industry rank of 147 out of 256 based on the ratings given to related companies.
A number of equities analysts recently weighed in on the company. Maxim Group set a $2.00 price objective on Co-Diagnostics and gave the company a “buy” rating in a report on Thursday, July 11th. Zacks Investment Research cut Co-Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, July 8th. Finally, HC Wainwright set a $2.00 target price on Co-Diagnostics and gave the company a “buy” rating in a research note on Friday, July 19th.
Co-Diagnostics (NASDAQ:CODX) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.01). Co-Diagnostics had a negative net margin of 19,057.66% and a negative return on equity of 430.95%. Equities analysts forecast that Co-Diagnostics will post -0.09 earnings per share for the current fiscal year.
Co-Diagnostics Company Profile
Co-Diagnostics, Inc, a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. Co-Diagnostics, Inc was founded in 2013 and is headquartered in Salt Lake City, Utah.
Featured Article: What does relative strength index mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.